Hanker et al. described that the FGFR and HER2 pathways can cooperate to promote tumor progression as a result of somatic mutations in genes related to the former pathway that could play a role in resistance to anti-HER2 drugs in HER2-positive BC tumors [25]. This evidence concerns the gene ERBB2 and neoplasm.